Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$438.91+2.32(+0.53%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.97-35.49(-4.46%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$289.81+2.51(+0.87%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.92-1.36(-2.33%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,460.30-35.84(-2.40%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.84+0.98(+0.96%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.31+4.31(+0.68%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.81+2.51(+0.87%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.55+5.04(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$196.95-3.34(-1.67%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.55+5.04(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.30-4.40(-2.56%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.50+1.70(+0.31%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ET

ALT · NASDAQ

Altimmune, Inc.

$2.13 +0.01 (+0.47%)

Company overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$414M
Employees
59
Headquarters
Gaithersburg, MD
Website
altimmune.com
CEO
Jerome Benedict Durso
Listed
May 26, 2017
P/E
-2.29
Dividend yield
13.11%

Company financials

Revenue
$36,000
Gross profit
-$14.9M
Operating income
-$96.9M
EBITDA
-$93.5M
Net income
-$91.1M
EPS
-$0.93
Total assets
$336M
Total debt
$35.8M
Gross margin
-41,519.44%
Net margin
-253,002.78%
Earnings yield
-43.66%

Revenue segmentation

By product (FY 2021)
By region (FY 2021)

No geographic segmentation.

Showing FY 2021

Price chart

1.932.352.773.193.61
ALT 1D NASDAQ O2.10H2.15L2.02C2.12+0.08 (+3.92%)Vol3.21M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ALTAltimmune, Inc. Press release Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 GlobeNewswire
ALTAltimmune, Inc. Press release Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution GlobeNewswire
ALTAltimmune, Inc. Press release Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026 GlobeNewswire
ALTAltimmune, Inc. Press release Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets Iridium Communications Inc. PR Newswire
ALTAltimmune, Inc. Stock news Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise MarketBeat
ALTAltimmune, Inc. Press release Altimmune to Participate in Stifel Cardiometabolic Forum GlobeNewswire
ALTAltimmune, Inc. Stock news Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT) Defense World
ALTAltimmune, Inc. Stock news Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? Zacks Investment Research
ALTAltimmune, Inc. Press release Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data GlobeNewswire
ALTAltimmune, Inc. Stock news Bank of America Corp DE Raises Position in Altimmune, Inc. $ALT Defense World
ALTAltimmune, Inc. Press release Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference GlobeNewswire
ALTAltimmune, Inc. Stock news Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus Zacks Investment Research
ALTAltimmune, Inc. Stock news Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? Zacks Investment Research
ALTAltimmune, Inc. Stock news ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus Zacks Investment Research
ALTAltimmune, Inc. Stock news Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT Defense World
ALTAltimmune, Inc. Stock news Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript Seeking Alpha
ALTAltimmune, Inc. Stock news Altimmune Q2 Earnings Call Highlights MarketBeat
ALTAltimmune, Inc. Press release Altimmune Announces Second Quarter 2026 Financial Results and Business Update GlobeNewswire
ALTAltimmune, Inc. Press release Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 GlobeNewswire
ALTAltimmune, Inc. Press release Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH GlobeNewswire
See more
FAQ

Questions about Altimmune, Inc.

What does Altimmune, Inc. do?
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
What is ALT's market cap?
Altimmune, Inc. (ALT) is a listed stock with a live quote. The latest market cap on this page is $414M.
Where is Altimmune, Inc. headquartered?
Altimmune, Inc. is headquartered in Gaithersburg, MD.
How do I get ALT news from the API?
Call GET /v1/news?tickers=ALT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ALT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ALT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs